Table 4 Comparison of pregnancy outcomes in the PPOS group and the GnRH antagonist group
PPOS group | GnRH antagonist group | P value | ||
|---|---|---|---|---|
FET cycles | 229 | 256 | ||
Endometrial preparation | 0.059 | |||
Natural cycles | 15.7% (36/229) | 23.0% (59/256) | ||
Drug-induced ovulation cycles | 10.9% (25/229) | 13.3% (34/256) | ||
Hormonal cycles | 73.8% (169/229) | 63.7% (163/256) | ||
Endometrial thickness (mm) | 8.6 ± 1.8 | 8.7 ± 1.9 | 0.625 | |
Biochemical pregnancy (%) | 65.9% (151/229) | 67.6% (173/256) | 0.772 | |
Clinical pregnancy (%) | 58.1% (133/229) | 59.8% (153/256) | 0.713 | |
Implantation rate (%) | 58.1% (133/229) | 59.8% (153/256) | 0.713 | |
Miscarriage rate (%) | 7.9% (12/151) | 16.8% (29/173) | 0.019* | |
Live birth rate (%) | 51.1% (117/229) | 46.9% (120/256) | 0.364 | |